Eli Lilly: China approves Alzheimer's treatment

(CercleFinance.com) - Eli Lilly has announced that the National Medical Products Administration (NMPA) in China has approved Kisunla for adults with early symptomatic Alzheimer's disease.


This includes people with mild cognitive impairment (MCI), as well as people with the mild dementia stage of Alzheimer's disease who have confirmed amyloid pathology.

China is the fourth major market in which Kisunla has been approved for use, following approvals in the USA, Japan and Great Britain.

In China, it is estimated that nearly 6% of people over 65 live with dementia, and that nearly 11% of people over 65 are expected to live with Alzheimer's disease by 2050.

Patients and their families want and deserve access to treatment with amyloid-targeted therapies, which could give them more time to do the things that matter most to them in the early stages of disease symptoms, said Lilly International said.

Kisunla continues to demonstrate very significant results for people with early symptomatic Alzheimer's disease and can now help improve the standard of care for people living with the disease in China.


Copyright (c) 2024 CercleFinance.com. All rights reserved.